MedTrace Logo

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

NCT00202995 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2010-10-18

No results posted yet for this study

Summary

Randomized study designed to look at the difference in relapse rates between patients remaining on their current interferon medication and those switched to Copaxone®

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Glatiramer Acetate

20 mg s.c. daily

DRUG

Betaseron

250 mg every other day

DRUG

Rebif

44 ug 3 times a week

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Helene Brooks · Teva Neuroscience, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2007-10-31
Completion
2007-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00202995 on ClinicalTrials.gov